RecruitingPhase 2NCT05499702

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction


Sponsor

Adrian Vella

Enrollment

20 participants

Start Date

Dec 15, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.


Eligibility

Min Age: 25 YearsMax Age: 65 Years

Inclusion Criteria3

  • We will recruit up to 20 weight-stable, subjects with type 2 diabetes
  • BMI ≥ 28 Kg/M2
  • Diabetes is managed by diet alone or a combination of oral agents

Exclusion Criteria7

  • History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • Contraindications to MRI (e.g. metal implants, claustrophobia).
  • Hematocrit \< 35%
  • TSH \< 0.4 or \> 5.5.
  • Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.

Interventions

BEHAVIORALCaloric Restriction

Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from "Nutritional Guidelines after Bariatric Surgery". Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake

DRUGHyperglycemic clamp

Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism


Locations(1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05499702


Related Trials